| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab170481-100μg |
100μg |
现货  |
| |
| Ab170481-1mg |
1mg |
现货 |
| |
| Ab170481-5mg |
5mg |
现货 |
| |
| Ab170481-10mg |
10mg |
期货 |
|
| 产品名称 | Alemtuzumab (anti-CD52), CD52 抗体 |
|---|---|
| 别名 | 阿伦单抗 | 阿仑单抗(抗 CD52) |
| 英文别名 | Alemtuzumab | Cambridge pathology 1 antigen antibody | CAMPATH 1 antibody | CAMPATH 1 antigen antibody | CAMPATH-1 antigen antibody | CD 52 antibody | CD52 antibody | CD52 antigen antibody | CD52 molecule antibody | CD52_HUMAN antibody | CDw52 antibody | |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | CD52 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | CD52 抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.2 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 194.0 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 216503-57-0 |
| 分子类型 | 抗体 |
Alemtuzumab (anti-CD52) (Ab170481) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD52 with Alemtuzumab (anti-CD52) (Ab170481) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156150).
Alemtuzumab (anti-CD52) (Ab170481) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD52 (red) with Alemtuzumab (anti-CD52) (Ab170481) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Alemtuzumab (anti-CD52) (Ab170481) - SEC
The purity of Alemtuzumab (anti-CD52) (Ab170481) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0303663 |
分析证书 | 24-03-25 | Ab170481 |
| ZJ24F0303662 |
分析证书 | 24-03-25 | Ab170481 |
| ZJ24F0303661 |
分析证书 | 24-03-25 | Ab170481 |
¥899.90
¥569.90
¥799.92
¥999.90
¥639.92
| 1. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. (1992) Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.. Clin Exp Immunol, 87 (1): (105-10). [PMID:1339322] [10.1021/op500134e] |
| 2. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA et al.. (2016) Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.. Neurology, 87 (19): (1985-1992). [PMID:27733571] [10.1021/op500134e] |
首页
400-620-6333
